Ayse Cefle

Ayse Cefle

Auto-generated profile, based on publicly available information

Ayse Cefle

Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2010 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MSMehmet Sayarlioglu
Mehmet Sayarlioglu
NYNergis Yuzbasioglu
Nergis Yuzbasioglu
MIMurat Inanc
Murat Inanc
SKSevil Kamali
Sevil Kamali
ACAyse Cefle
Ayse Cefle
OAOrhan Aral
Orhan Aral


6 February 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ZSZiver Sahin
Ziver Sahin
MBMuge Bıcakcıgil
Muge Bıcakcıgil
KAKenan Aksu
Kenan Aksu
SKSevil Kamali
Sevil Kamali
SAServet Akar
Servet Akar
TGthe Turkish Takayasu Study Group
the Turkish Takayasu Study Group
Introduction: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. Methods: TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. Results: We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). Conclusions: In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further.

11 December 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ACAyse Cefle
Ayse Cefle
MIMurat Inanc
Murat Inanc
MSMehmet Sayarlioglu
Mehmet Sayarlioglu
SKSevil Kamali
Sevil Kamali
AGAhmet Gul
Ahmet Gul
MKMeral Konice
Meral Konice

20 July 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BKBulent Kara
Bulent Kara
ZEZelal Ekinci
Zelal Ekinci
SSSezgin Sahin
Sezgin Sahin
MGMesut Gungor
Mesut Gungor
AGAyfer Sakarya Gunes
Ayfer Sakarya Gunes
OKOzgur Kasapcopur
Ozgur Kasapcopur

6 July 2022 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SSSevgi Subasi
Sevgi Subasi
KKKubra Demirci Kucuk
Kubra Demirci Kucuk
SSSenar San
Senar San
ACAyse Cefle
Ayse Cefle
ETEcem Onder Tokuc
Ecem Onder Tokuc
AYAyten Yazici
Ayten Yazici